Tachyon Receives IND Clearance from FDA to Develop Novel KDM4 Inhibitor TACH101 for Advanced Solid Tumors
HOUSTON–(BUSINESS WIRE)–Tachyon Therapeutics, Inc. (“Tachyon” or “the Company”), a private biotechnology company developing transformative cancer therapies against novel targets, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to develop TACH101 for the treatment of advanced solid tumors. “The approval of this IND marks a … [Read more…]
